Development of SHP2 inhibitors for targeted anti-cancer therapy

开发用于靶向抗癌治疗的SHP2抑制剂

基本信息

  • 批准号:
    10113552
  • 负责人:
  • 金额:
    $ 42.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Proper level of protein tyrosine phosphorylation, coordinated by the reversible and dynamic action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is essential for cell growth and survival. Aberrant protein tyrosine phosphorylation, due to perturbed balance between the activities of PTKs and PTPs, is linked to the etiology of numerous human diseases, including cancer. Consequently, signaling events driven by dysregulated protein tyrosine phosphorylation offer a rich source of molecular targets for therapeutic interventions. The therapeutic potential for such a targeted approach has been well established by the more than two-dozen PTK inhibitors that are already used in the clinic. However, acquired resistance to PTK inhibitors limit durable responses. Therefore, new targets and innovative strategies are desperately needed for more effective therapy. Given the reversible nature of protein tyrosine phosphorylation, there is enormous potential to modulate disease progression at the level of PTPs. To this end, the Src homology 2 (SH2) domain containing protein tyrosine phosphatase-2 (SHP2), encoded by the Ptpn11 gene, has been established as a positive signal transducer, required for receptor PTK-mediated Ras activation. In addition, considerable evidence indicates that SHP2 is a bona fide oncoprotein. Activating SHP2 mutations are found in leukemia and solid tumors. Moreover, given the obligatory requirement of SHP2 in growth factor-mediated pathways, thwarting SHP2 activity may also prove effective for cancers caused by abnormal activation of receptor PTKs, some of which respond poorly to kinase inhibitor monotherapy. Indeed, recent studies indicate that SHP2 is a central node in intrinsic and acquired resistance to tyrosine kinase targeted cancer drugs. We hypothesize that potent and selective small molecule SHP2 inhibitors can serve as novel anti-cancer agents. Although PTP- based drug discovery has been a challenge in the field, due to difficulty in developing potent, selective and bioavailable small molecule inhibitors, we have identified a novel hit compound 11a-1 that inhibits SHP2 with an IC50 of 200 nM and over 5-fold selectivity against a large panel of PTPs. Moreover, this inhibitor efficaciously blocks growth factor stimulated Erk1/2 and Akt activation, cell proliferation, and tumor growth in a number of in vitro and in vivo systems. The overall goal of this proposal is to employ a multifaceted and integrated approach to optimize the existing hit 11a-1 into preclinical leads to assess the therapeutic potential of targeting SHP2 for cancer treatment. Successful completion of this project will create a solid foundation upon which novel SHP2-based targeted anti-cancer therapy can be developed. Moreover, success of this project will also galvanize the development of therapeutics targeting other members of the PTP family, ultimately impacting broadly on human health.
适当水平的蛋白质酪氨酸磷酸化,由蛋白质的可逆和动态作用协调 酪氨酸激酶(PTK)和蛋白酪氨酸磷酸酶(PTPs)对于细胞生长和存活是必需的。 异常的蛋白酪氨酸磷酸化,由于PTKs和PTPs活性之间的平衡被扰乱, 与包括癌症在内的许多人类疾病的病因有关。因此,信号事件驱动 通过失调的蛋白质酪氨酸磷酸化为治疗提供了丰富的分子靶点来源, 干预措施。这种靶向方法的治疗潜力已经被更多的人所证实。 超过二十几种已经在临床上使用的PTK抑制剂。然而,获得性耐药PTK 抑制剂限制了持久的反应。因此,迫切需要新的目标和创新战略, 更有效的治疗。鉴于蛋白质酪氨酸磷酸化的可逆性, 在PTP水平调节疾病进展的潜力。为此,Src同源2(SH 2)结构域 含有蛋白酪氨酸磷酸酶-2(SHP 2),由Ptpn 11基因编码,已被确定为一种 阳性信号转导子,受体PTK介导的Ras激活所需。此外,相当多的 有证据表明SHP 2是一种真正的癌蛋白。在白血病中发现了激活SHP 2突变, 实体瘤此外,考虑到生长因子介导的途径中对SHP 2的强制性要求, 阻碍SHP 2活性也可以证明对由受体PTK的异常激活引起的癌症有效, 其中一些对激酶抑制剂单一疗法反应差。事实上,最近的研究表明,SHP 2是一种 酪氨酸激酶靶向抗癌药物的内在和获得性耐药性的中心节点。我们假设 有效的和选择性的小分子SHP 2抑制剂可用作新的抗癌剂。虽然PTP- 由于难以开发有效的、选择性的和有效的药物, 生物可利用的小分子抑制剂,我们已经确定了一种新的命中化合物11 a-1,抑制SHP 2, IC 50为200 nM,对大量PTP的选择性超过5倍。此外,这种抑制剂 有效地阻断生长因子刺激的Erk 1/2和Akt活化、细胞增殖和肿瘤生长, 体外和体内系统的数量。这项建议的总体目标是采用一种多方面和 将现有的hit 11 a-1优化为临床前线索的综合方法,以评估治疗潜力 靶向SHP 2用于癌症治疗。这个项目的成功完成将为 基于此可以开发新的基于SHP 2的靶向抗癌疗法。此外,这一成功 该项目还将促进针对PTP家族其他成员的治疗方法的开发, 最终对人类健康产生广泛影响。

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Insulin regulates POMC neuronal plasticity to control glucose metabolism.
  • DOI:
    10.7554/elife.38704
  • 发表时间:
    2018-09-19
  • 期刊:
  • 影响因子:
    7.7
  • 作者:
    Dodd GT;Michael NJ;Lee-Young RS;Mangiafico SP;Pryor JT;Munder AC;Simonds SE;Brüning JC;Zhang ZY;Cowley MA;Andrikopoulos S;Horvath TL;Spanswick D;Tiganis T
  • 通讯作者:
    Tiganis T
Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
  • DOI:
    10.1021/acs.jmedchem.0c00302
  • 发表时间:
    2020-09-10
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Ruddraraju KV;Aggarwal D;Niu C;Baker EA;Zhang RY;Wu L;Zhang ZY
  • 通讯作者:
    Zhang ZY
Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation.
疾病相关 SHP2 突变体的相分离是 MAPK 过度激活的基础。
  • DOI:
    10.1016/j.cell.2020.09.002
  • 发表时间:
    2020-10-15
  • 期刊:
  • 影响因子:
    64.5
  • 作者:
    Zhu G;Xie J;Kong W;Xie J;Li Y;Du L;Zheng Q;Sun L;Guan M;Li H;Zhu T;He H;Liu Z;Xia X;Kan C;Tao Y;Shen HC;Li D;Wang S;Yu Y;Yu ZH;Zhang ZY;Liu C;Zhu J
  • 通讯作者:
    Zhu J
Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems.
  • DOI:
    10.3390/ijms22115797
  • 发表时间:
    2021-05-28
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Zhong W;Shahbaz O;Teskey G;Beever A;Kachour N;Venketaraman V;Darmani NA
  • 通讯作者:
    Darmani NA
The Contribution of Phospholipase C in Vomiting in the Least Shrew (Cryptotis Parva) Model of Emesis.
  • DOI:
    10.3389/fphar.2021.736842
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Zhong W;Darmani NA
  • 通讯作者:
    Darmani NA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhong-Yin Zhang其他文献

Zhong-Yin Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhong-Yin Zhang', 18)}}的其他基金

Assay Development and High Throughput Screening Core
检测开发和高通量筛选核心
  • 批准号:
    10017160
  • 财政年份:
    2019
  • 资助金额:
    $ 42.9万
  • 项目类别:
Assay Development and High Throughput Screening Core
检测开发和高通量筛选核心
  • 批准号:
    10250439
  • 财政年份:
    2019
  • 资助金额:
    $ 42.9万
  • 项目类别:
Assay Development and High Throughput Screening Core
检测开发和高通量筛选核心
  • 批准号:
    10684144
  • 财政年份:
    2019
  • 资助金额:
    $ 42.9万
  • 项目类别:
Development of SHP2 inhibitors for targeted anti-cancer therapy
开发用于靶向抗癌治疗的SHP2抑制剂
  • 批准号:
    9891029
  • 财政年份:
    2017
  • 资助金额:
    $ 42.9万
  • 项目类别:
Development of SHP2 inhibitors for targeted anti-cancer therapy
开发用于靶向抗癌治疗的SHP2抑制剂
  • 批准号:
    9311459
  • 财政年份:
    2017
  • 资助金额:
    $ 42.9万
  • 项目类别:
Target Mycobacterium Protein Tyrosine Phosphatase B for Anti-Tuberculosis Agents
用于抗结核药物的靶分枝杆菌蛋白酪氨酸磷酸酶 B
  • 批准号:
    8089759
  • 财政年份:
    2010
  • 资助金额:
    $ 42.9万
  • 项目类别:
Small Molecule Inhibitors for the Oncogenic Protein Tyrosine Phosphatase SHP2
致癌蛋白酪氨酸磷酸酶 SHP2 的小分子抑制剂
  • 批准号:
    8067184
  • 财政年份:
    2010
  • 资助金额:
    $ 42.9万
  • 项目类别:
Small Molecule Inhibitors for the Oncogenic Protein Tyrosine Phosphatase SHP2
致癌蛋白酪氨酸磷酸酶 SHP2 的小分子抑制剂
  • 批准号:
    8260331
  • 财政年份:
    2010
  • 资助金额:
    $ 42.9万
  • 项目类别:
Small Molecule Inhibitors for the Oncogenic Protein Tyrosine Phosphatase SHP2
致癌蛋白酪氨酸磷酸酶 SHP2 的小分子抑制剂
  • 批准号:
    8680177
  • 财政年份:
    2010
  • 资助金额:
    $ 42.9万
  • 项目类别:
Small Molecule Inhibitors for the Oncogenic Protein Tyrosine Phosphatase SHP2
致癌蛋白酪氨酸磷酸酶 SHP2 的小分子抑制剂
  • 批准号:
    8490684
  • 财政年份:
    2010
  • 资助金额:
    $ 42.9万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 42.9万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了